Proteolytic Enzyme Induction Within the Human Myocardial Interstitium
Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
A robust release of endothelin-1-1 (ET) with subsequent ETA subtype receptor (ET-AR)
activation occurs in patients following cardiac surgery requiring cardiopulmonary bypass
(CPB). Increased ET-AR activation has been identified in patients with poor left ventricular
(LV) function (reduced ejection fraction; EF). Accordingly, this study tested the hypothesis
that a selective ET-AR antagonist (ET-ARA) administered peri-operatively would favorably
affect post-CPB hemodynamic profiles in patients with a pre-existing poor LVEF.